<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00553943</url>
  </required_header>
  <id_info>
    <org_study_id>R-C5R 2006</org_study_id>
    <secondary_id>R-C5R</secondary_id>
    <nct_id>NCT00553943</nct_id>
  </id_info>
  <brief_title>Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis</brief_title>
  <official_title>Prospective Multicentre Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® by Intrathecal Injection in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lymphoma Study Association</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the rate of complete response (CR and UCR) at the end
      of a course of immuno-chemotherapy:

        -  before cerebral radiotherapy for PCL

        -  after the course of immuno-chemotherapy for aggressive lymphomas with neuromeningeal
           involvement Toxicity of the protocol Overall survival Survival without relapse Long-term
           incidence of neurocognitive toxicity
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to treatment (CR/PR)</measure>
    <time_frame>End of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity, Overall survival, Time to progression</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab, Cytarabine</intervention_name>
    <description>Intravenous chemotherapy associated with IV rituximab and intrathecal cytarabine</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary cerebral or oculocerebral NHL not previously treated with chemotherapy or
             radiotherapy and diffuse large B-cell lymphomas, with cerebral and / or neuromeningeal
             involvement at diagnosis.

          -  Diagnosis proved by histological or cytological examination of cerebral specimens, CSF
             or vitreous humour.

          -  Diffuse large cell CD20+ lymphoma.

          -  Men or women between the ages of 18 and 60 years.

          -  Presence of a measurable target to evaluate response.

          -  Negative serological tests for HIV, hepatitis B (except in cases of vaccination),
             hepatitis C.

          -  Life-expectancy ≥ 3 months

          -  Patient having given written consent to participate in this study.

        Exclusion Criteria:

          -  CD20- lymphoma.

          -  History of indolent lymphoma, treated or untreated.

          -  Contraindication for one of the products used in polychemotherapy.

          -  Known hypersensitivity to mouse antibodies.

          -  Absence of measurable target to evaluate response.

          -  History of cancer in the 5 years prior to inclusion except for cutaneous basocellular
             carcinomas and non-invasive carcinomas of the neck of the uterus.

          -  Cardiac contraindication to treatment with anthracyclines or to hyperhydration:

        SEVERE DISTURBANCE OF HEART RHYTHM VENTRICULAR EJECTION FRACTION BELOW 50% HISTORY OF
        RECENT MYOCARDIAL INFARCTION

          -  Previously known severe renal insufficiency and/or creatinaemia &gt;150 µM/L (apart from
             invasion of the kidneys by the lymphoma).

          -  Total bilirubin &gt;30 µmol/L, ASAT, ALAT &gt;2.5 times the upper normal value (apart from
             invasion of the liver by the lymphoma).

          -  Insufficient medullary reserve: PNL &lt; 1 G/L and platelets &lt;100 G/L (apart from
             invasion of the medulla by the lymphoma).

          -  History of organ transplantation or other causes of severe immunosuppression.

          -  Pregnant woman.

          -  Patient incapable of keeping to regular monitoring.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herve Ghesquieres, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Groupe d'Etude des Lymphomes de l'Adulte (GELA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HERVE GHESQUIERES, MD</last_name>
    <phone>33 (0)4 78 78 28 28</phone>
    <email>ghesquie@lyon.fnclcc.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christelle DA-CRUZ</last_name>
    <phone>33 (0)4 72 66 93 33</phone>
    <email>christelle.da-cruz@gelarc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH d'Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>F-74011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernadette Corront, MD</last_name>
      <phone>33 (0)4 50 88 33 28</phone>
    </contact>
    <investigator>
      <last_name>Bernadette Corront, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>F-84902</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hacene ZERAZHI, MD</last_name>
      <email>hzerazhi@ch-avignon.fr &lt;hzerazhi@ch-avignon.fr&gt;</email>
    </contact>
    <investigator>
      <last_name>Hacene ZERAZHI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Bayonne</name>
      <address>
        <city>Bayonne</city>
        <zip>F-64100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederic BAUDUER, MD</last_name>
      <phone>33 (0)5 59 44 38 32</phone>
      <email>fbauduer001@chcb.rss.fr &lt;fbauduer001@chcb.rss.fr&gt;</email>
    </contact>
    <investigator>
      <last_name>Frederic Bauduer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>F-93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Fain, PhD</last_name>
      <phone>33 (0)1 48 02 63 80</phone>
      <email>olivier.fain@jvr.ap-hop-paris.fr &lt;olivier.fain@jvr.ap-hop-paris.fr&gt;</email>
    </contact>
    <investigator>
      <last_name>olivier Fain, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>F-33300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Fitoussi, MD</last_name>
      <phone>33 (0)5 56 43 73 54</phone>
      <email>o.fitoussi@bordeauxnord.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Brive</name>
      <address>
        <city>Brive la Gaillarde</city>
        <zip>F-19190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Lefort, MD</last_name>
      <phone>33 (0)5 55 92 60 52</phone>
    </contact>
    <investigator>
      <last_name>Sophie Lefort, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clemenceau</name>
      <address>
        <city>Caen</city>
        <zip>F-14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margarete Macro, MD</last_name>
      <phone>33 (0)2 31 27 25 39</phone>
      <email>macro-m@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Margarete Macro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>F-14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Fruchart, MD</last_name>
      <phone>33 (0)2 31 45 50 12</phone>
      <email>c.fruchart@baclesse.fr</email>
    </contact>
    <investigator>
      <last_name>Chritophe Fruchart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Chambery</name>
      <address>
        <city>Chambery</city>
        <zip>F-73011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel Blanc, MD</last_name>
      <phone>33 (0)4 79 96 51 05</phone>
      <email>michel.blanc@ch-chambery.fr</email>
    </contact>
    <investigator>
      <last_name>Moichel Blanc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Chartres</name>
      <address>
        <city>Chartres</city>
        <zip>F-28018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lina ALJASSEM, MD</last_name>
      <phone>33 (0)2 37 30 33 47</phone>
      <email>aljassem@ch-chartres.fr</email>
    </contact>
    <investigator>
      <last_name>Lina ALJASSEM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Gilles de Corbeil</name>
      <address>
        <city>Corbeil Essone</city>
        <zip>F-91108</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Devidas</last_name>
      <email>alain.devidas@ch-sud-francilien.fr</email>
    </contact>
    <investigator>
      <last_name>Alain Devidas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>F-94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corinne Haioun, PhD</last_name>
      <phone>33(0)1 49 81 20 51</phone>
      <email>corinne.haioun@hmn.ap-hop-paris.fr</email>
    </contact>
    <investigator>
      <last_name>Corinne Haioun, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Le Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>F-21034</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rene-Olivier Casasnovas, MD</last_name>
      <phone>33 (0)3 80 29 50 41</phone>
      <email>olivier.casasnovas@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Rene-Olivier Casasnovas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <zip>F-59385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Wetterwald, MD</last_name>
      <phone>33 (0)3 28 28 56 33</phone>
      <email>marc.wetterwald@ch-dunkerque.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Wetterwald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Kremlin Bicêtre</city>
        <zip>F-94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Besson, MD</last_name>
      <phone>33 (0)1 45 21 20 16</phone>
      <email>caroline.besson@bct.ap-hop-paris.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline Besson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>La Rochelle</city>
        <zip>F-17019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel Fleck, MD</last_name>
      <email>emmanuel.fleck@ch-larochelle.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel Fleck, md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Andre Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <zip>F-78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvie Csataigne, PhD</last_name>
      <phone>33 (0)1 39 63 89 09</phone>
      <email>scastaigne@ch-versailles.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvie Castaigne, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lens</name>
      <address>
        <city>Lens</city>
        <zip>F-62307</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Morel, MD</last_name>
      <phone>33 (0)3 21 69 13 94</phone>
      <email>pmorel@ch-lens.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Morel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Vincent de Paul</name>
      <address>
        <city>Lille</city>
        <zip>F-59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Rose, MD</last_name>
      <email>rose.christian@ghicl.net</email>
    </contact>
    <investigator>
      <last_name>Christian Rose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>F-59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck Morschhauser, MD</last_name>
      <email>f-morschhauser@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Franck Morschhauser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>F-87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique Bordessoule, PhD</last_name>
      <phone>33 (0)5 55 05 66 42</phone>
      <email>bordesso@unilim.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique Bordessoule, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>F-69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herve Ghesquieres, MD</last_name>
      <phone>33 (0)4 78 78 27 37</phone>
    </contact>
    <investigator>
      <last_name>Herve Ghesquieres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital des Chanaux</name>
      <address>
        <city>Macon</city>
        <zip>F-71018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amine Belhabri, MD</last_name>
      <phone>33 (0)3 85 27 53 33</phone>
      <email>ambelhabri@ch-macon.fr</email>
    </contact>
    <investigator>
      <last_name>Amine Belhabry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>F-77100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wajed ABARAH, MD</last_name>
      <phone>33 (0)1 64 35 38 75</phone>
      <email>w-abarah@ch-meaux.fr</email>
    </contact>
    <investigator>
      <last_name>Wajed ABARAH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bon Secours</name>
      <address>
        <city>Metz</city>
        <zip>F-57038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard Christian, MD</last_name>
      <phone>33 (0)3 87 55 33 04</phone>
      <email>b.christian@chr-metz-thionville.rss.fr</email>
    </contact>
    <investigator>
      <last_name>Bernard Christian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Emile Muller</name>
      <address>
        <city>Mulhouse</city>
        <zip>F-68070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Claude Eisenmann, MD</last_name>
      <phone>03 89 64 77 55</phone>
      <email>eisenmannj@ch-mulhouse.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Claude Eisenmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>F-06054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine Thyss, PhD</last_name>
      <phone>33 (0)4 92 03 10 47</phone>
      <email>antoine.thyss@cal.nice.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine Thyss, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>F-75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Gisselbrecht, PhD</last_name>
      <phone>33 (0)1 42 49 92 96</phone>
      <email>christian.gisselbrecht@sls.ap-hop-paris.fr</email>
    </contact>
    <investigator>
      <last_name>Christian Gisselbrecht, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>F-75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Delarue, MD</last_name>
      <phone>33 (0)1 44 49 52 82</phone>
      <email>richard.delarue@nck.ap-hop-paris.fr</email>
    </contact>
    <investigator>
      <last_name>Richard Delarue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Perpigan</name>
      <address>
        <city>Perpignan</city>
        <zip>F-66046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier Vallantin, MD</last_name>
      <phone>33 (0)4 68 61 64 48</phone>
      <email>xavier.vallantin@ch-perpignan.fr</email>
    </contact>
    <investigator>
      <last_name>xavier Perpignan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>F-69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles salles, PhD</last_name>
      <phone>33 (0)4 78 86 43 02</phone>
      <email>gilles.salles@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles Salles, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>F-76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herve Tilly, PhD</last_name>
      <phone>33 (0)2 32 08 22 23</phone>
      <email>htilly@rouen.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Herve Tilly, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de St Germain</name>
      <address>
        <city>St Germain en Laye</city>
        <zip>F-78108</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mickaël AZAGURY, MD</last_name>
      <phone>33 (0)1 39 27 49 51</phone>
      <email>mazagury@chi-poissy-st-germain.fr &lt;mazagury@chi-poissy-st-germain.fr&gt;</email>
    </contact>
    <investigator>
      <last_name>Mickaël Azagury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>F-31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guy Laurent, PhD</last_name>
      <phone>33 (0)5 61 77 20 78</phone>
    </contact>
    <investigator>
      <last_name>Guy Laurent, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Serge Bologna, MD</last_name>
      <phone>33 (o)3 83 15 32 82</phone>
      <email>s.bologna@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Serge Bologna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gela.org</url>
  </link>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2007</study_first_submitted>
  <study_first_submitted_qc>November 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2007</study_first_posted>
  <last_update_submitted>October 22, 2010</last_update_submitted>
  <last_update_submitted_qc>October 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Herve Ghesquieres</name_title>
    <organization>GELA</organization>
  </responsible_party>
  <keyword>lymphoma</keyword>
  <keyword>cerebral lymphoma</keyword>
  <keyword>central nervous system</keyword>
  <keyword>cytarabine</keyword>
  <keyword>rituximab</keyword>
  <keyword>Diffuse large B-cell lymphomas, with cerebral or neuromeningeal involvement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

